Back to News
Market Impact: 0.35
GSK: ViiV Healthcare Secures FDA Approval For Tivicay PD In Young Children With HIV
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
The U.S. FDA approved ViiV Healthcare’s Tivicay PD for pediatric HIV treatment in combination with other antiretrovirals, covering patients weighing at least 2 kg, including eligible newborns. The approval expands the drug’s label into a new, high-need segment and supports growth for the franchise.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
GSK0.60
More News
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Cerebras Is About as Big as Nvidia's Data Center Business Was Nearly a Decade Ago. The Similarities Mostly End There.
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts
- How to Automate Equity Research Workflows: A Control-First Guide